Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade 3-4 drug-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer immunology research 2016-04, Vol.4 (4), p.345-353
Hauptverfasser:	Weber, Jeffrey, Gibney, Geoffrey, Kudchadkar, Ragini, Yu, Bin, Cheng, Pingyan, Martinez, Alberto J, Kroeger, Jodie, Richards, Allison, McCormick, Lori, Moberg, Valerie, Cronin, Heather, Zhao, Xiuhua, Schell, Michael, Chen, Yian Ann
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biomarkers Cohort Studies Combined Modality Therapy Disease Progression Drug Resistance, Neoplasm Female Humans Immunophenotyping Ipilimumab Kaplan-Meier Estimate Male Melanoma - drug therapy Melanoma - immunology Melanoma - mortality Melanoma - pathology Middle Aged Myeloid Cells - immunology Myeloid Cells - metabolism Neoplasm Metastasis Neoplasm Staging Nivolumab Retreatment Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!